Long-Term Data from CANbridge Pharmaceuticals CAN008 Phase 1/2 Trial in Glioblastoma Multiforme Shows 67% Five-Year Overall Survival Rate Compared to 8.2% in Institutional Database

-Data to be Presented at the ESMO Sarcoma and Rare Cancers Annual Congress

-83% overall survival at two years vs. 34.3% OS from institutional database

-17.95 months median progression-free survival vs. 5.8 months PFS in historical group

Mar 17, 2023

CANbridge Pharmaceuticals Announces CAN008 Phase 1/2 Glioblastoma Multiforme Abstract Accepted by the ESMO Sarcoma and Rare Cancers Congress

Mar 13, 2023

CANbridge Named to South Reviews “2022 Annual List of Chinese Social Values”

Feb 24, 2023

Article from Cloud-based Medicine Studio | A national authoritative medical organization for rare diseases will be established, and the second list of rare diseases will be updated
(attachments: the first list and the national reimbursement drug list)

Jan 31, 2023

First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 2 Trial for the Treatment of Gaucher Disease in China

Jan 18, 2023

CANbridge Congratulates Apogenix on First Patient Dosed in Asunercept (CAN008) Phase 3 Trial for the Treatment of COVID-19

-CANbridge holds exclusive rights for the development of CAN008 for any indication in Greater China

-CAN008 currently in Phase 2 trial for the treatment of glioblastoma multiforme in China

Jan 05, 2023

CANbridge Consolidates Gene Therapy Portfolio

-Secures Exclusive Global Rights to Potentially Best-in-Class Spinal Muscular Atrophy Gene Therapy from UMass Chan Medical School

-Completes Technology Transfer of Two Gene Therapies for Lysomal Storage Diseases

Jan 04, 2023